Flurazepam
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Flurazepam
Flurazepam: Known uses and market status in Canada
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidate indications for Flurazepam. Every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 0 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 00521698 | FLURAZEPAM | Valid | |
| 00521701 | FLURAZEPAM | Valid |
Safety Considerations
- Contraindications and cautions from the knowledge graph (not label text): The knowledge graph links flurazepam with the following conditions as contraindications:
- Respiratory: sleep apnea syndromes, respiratory failure, lung disease
- Organ function: liver disease, kidney disease, gallbladder disease
- Psychiatric: psychotic disorders, schizophreniform and schizoaffective disorders, personality disorder, anxiety disorder, neurotic disorder, dysthymic disorder, intermittent explosive disorder
- Substance use: substance-related disorders and substance abuse/dependence
- Metabolic: porphyria
- Drug Interactions: The interaction query returned about 100 entries. The main ones are:
- Major: morphine, including liposomal morphine (additive central nervous system and respiratory depression)
- Moderate: bupropion, omeprazole, cimetidine, clarithromycin, dronabinol, nabilone, metoclopramide, opium, sibutramine, teduglutide
- Minor: antacids and mineral agents such as magnesium oxide, calcium carbonate and aluminum hydroxide
- Literature-based concerns: Residual sedation and impaired driving performance, risks in older adults, and rebound insomnia after discontinuation.
Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.